Matthew Biegler
Stock Analyst at Oppenheimer
(3.46)
# 2,313
Out of 4,600 analysts
398
Total ratings
39.7%
Success rate
3.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Reiterated: Buy | $50 | $32.53 | +53.70% | 24 | Jul 31, 2026 | |
| GILD Gilead Sciences | Rated: Hold | n/a | $135.25 | - | 16 | Jun 15, 2026 | |
| CTMX CytomX Therapeutics | Rated: Hold | n/a | $3.32 | - | 12 | Jun 15, 2026 | |
| ARVN Arvinas | Rated: Hold | n/a | $9.00 | - | 17 | Jun 15, 2026 | |
| IDYA IDEAYA Biosciences | Rated: Hold | n/a | $36.11 | - | 20 | Jun 15, 2026 | |
| ORIC ORIC Pharmaceuticals | Rated: Hold | n/a | $13.47 | - | 23 | Jun 15, 2026 | |
| RLAY Relay Therapeutics | Rated: Hold | n/a | $19.54 | - | 18 | Jun 15, 2026 | |
| OLMA Olema Pharmaceuticals | Rated: Hold | n/a | $11.76 | - | 23 | Jun 15, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 | $1.90 | +268.42% | 9 | May 14, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Reiterated: Buy | $9 | $4.88 | +84.43% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $24.69 | +13.41% | 23 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.23 | +631.71% | 14 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.06 | - | 11 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $865 | $760.66 | +13.72% | 13 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $16.69 | +169.62% | 2 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $4.10 | +631.71% | 7 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $8.87 | +148.03% | 4 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.80 | +294.74% | 22 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.56 | +412.82% | 13 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.57 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.16 | n/a | 5 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $22.25 | n/a | 13 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11.24 → $4.21 | $0.36 | n/a | 12 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.16 | n/a | 15 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $0.1942 | n/a | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.7034 | n/a | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.26 | n/a | 6 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $50 | $1.23 | n/a | 15 | Feb 17, 2022 |
Tyra Biosciences
Jul 31, 2026
Reiterated: Buy
Price Target: $50
Current: $32.53
Upside: +53.70%
Gilead Sciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $135.25
Upside: -
CytomX Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $3.32
Upside: -
Arvinas
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $9.00
Upside: -
IDEAYA Biosciences
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $36.11
Upside: -
ORIC Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $13.47
Upside: -
Relay Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $19.54
Upside: -
Olema Pharmaceuticals
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $11.76
Upside: -
Allogene Therapeutics
May 14, 2026
Reiterated: Buy
Price Target: $7
Current: $1.90
Upside: +268.42%
Zentalis Pharmaceuticals
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $4.88
Upside: +84.43%
May 13, 2026
Reiterated: Buy
Price Target: $28
Current: $24.69
Upside: +13.41%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $1.23
Upside: +631.71%
May 12, 2026
Rated: Hold
Price Target: n/a
Current: $8.06
Upside: -
Apr 30, 2026
Reiterated: Buy
Price Target: $865
Current: $760.66
Upside: +13.72%
Mar 27, 2026
Reiterated: Buy
Price Target: $45
Current: $16.69
Upside: +169.62%
Mar 13, 2026
Reiterated: Buy
Price Target: $30
Current: $4.10
Upside: +631.71%
Mar 6, 2026
Reiterated: Buy
Price Target: $22
Current: $8.87
Upside: +148.03%
Dec 8, 2025
Reiterated: Buy
Price Target: $15
Current: $3.80
Upside: +294.74%
Nov 14, 2025
Reiterated: Buy
Price Target: $8
Current: $1.56
Upside: +412.82%
May 14, 2025
Reiterated: Hold
Price Target: n/a
Current: $2.57
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: n/a
Current: $3.16
Upside: n/a
Dec 9, 2024
Maintained: Buy
Price Target: $160
Current: $22.25
Upside: n/a
Aug 14, 2023
Maintained: Buy
Price Target: $11.24 → $4.21
Current: $0.36
Upside: n/a
Jul 31, 2023
Rated: Hold
Price Target: n/a
Current: $16.16
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $18
Current: $0.1942
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.7034
Upside: n/a
Dec 22, 2022
Downgraded: Hold
Price Target: n/a
Current: $2.26
Upside: n/a
Feb 17, 2022
Maintained: Buy
Price Target: $8 → $50
Current: $1.23
Upside: n/a